empagliflozin

Overview

Empagliflozin is a selective inhibitor of sodium glucose cotransporter-2 (SGLT2 inhibitor), a membrane transporter responsible for reabsorbing the majority of filtered glucose in the proximal tubule of the kidney. By blocking SGLT2, empagliflozin promotes urinary glucose excretion, thereby lowering blood glucose levels independently of insulin secretion. Originally approved for the management of type 2 diabetes mellitus (T2DM), its clinical profile has expanded considerably to encompass cardioprotective and renoprotective indications, including heart failure with reduced and preserved ejection fraction and chronic kidney disease. Its mechanism of action is complementary to agents targeting insulin secretion pathways, such as dipeptidyl peptidase-4 (DPP-4) inhibitors and metformin formulations, making it a frequent partner in combination regimens.

Beyond glycemic control, empagliflozin exerts pleiotropic effects across multiple organ systems, including the cardiovascular system, kidneys, and gut epithelium. These actions are mediated through metabolic, anti-inflammatory, and cytoprotective pathways — including modulation of AMPK/mTOR signaling, reduction of proinflammatory cytokines, and attenuation of oxidative stress — that operate partly or entirely independently of SGLT2 inhibition itself. This breadth of activity has made empagliflozin a prominent subject of investigation in preclinical and clinical research well beyond its original indication.

Focus of Latest Publications

Recent publications on empagliflozin have focused on its comparative effectiveness in real-world cardiometabolic care and on mechanistic studies exploring tissue-protective effects in diabetes-related complications. In a prospective cohort study in heart failure with reduced ejection fraction, empagliflozin and dapagliflozin were described as sodium-glucose cotransporter-2 inhibitors with equivalent Class IA guideline recommendations, providing a clinical context for head-to-head evaluation. A nationwide propensity-matched study in adults with type 2 diabetes compared empagliflozin with dapagliflozin and with dipeptidyl peptidase-4 inhibitors, finding broadly similar outcomes versus dapagliflozin but lower risks of hypoglycemia and all-cause hospitalization, as well as lower risks of all-cause hospitalization and kidney events versus DPP-4 inhibitors. The authors emphasized that these associations were observational and should be interpreted cautiously.

Several studies examined empagliflozin in combination with other agents or in disease models beyond glucose lowering. In diabetic kidney disease, empagliflozin was studied alongside Morin in HK2 cells and db/db mice, where it was reported to indirectly downregulate DAPK1 through relief of endoplasmic reticulum stress and to improve renal structure, blood glucose, urinary albumin-to-creatinine ratio, and kidney stress markers; the combination produced greater benefits than either treatment alone. In diabetic myocardial ischemia/reperfusion injury, empagliflozin was combined with pyridoxamine, and the dual treatment was reported to suppress advanced glycation end-products accumulation, mitigate mitochondrial damage and PANoptosis, and improve cardiac recovery after ischemia/reperfusion in diabetic mice. Another randomized phase 3 trial evaluated anagliptin added to metformin and empagliflozin in type 2 diabetes, reflecting continued interest in empagliflozin as part of combination therapy, although the abstract provided only the study aim.

Mechanistic work also linked empagliflozin to barrier protection and organ-specific stress responses. In glycogen storage disease type Ib with refractory inflammatory bowel disease, empagliflozin was reported to promote ulcer healing and mucin production in patients, reduce disease severity and goblet cell depletion in a murine model, and restore the colonic mucus barrier through an AMPK/SOX4/MUC2 pathway in intestinal epithelial cells. In ischemia/reperfusion models of the heart, empagliflozin improved metabolic profiles, myocardial and coronary function, contractility, coronary flow recovery, and markers of injury, inflammation, oxidative stress, fibrosis, and angiocrine imbalance in diabetic and non-diabetic rats; in human cardiac microvascular endothelial cells and cardiomyocytes, it preserved eNOS-related signaling, mitochondrial membrane potential, and cell survival under high-glucose and hypoxia/reoxygenation conditions. Additional work suggested potential cognitive benefits in diabetic rats, where empagliflozin showed stronger in silico interactions than dapagliflozin with targets including SGLT1/2 and acetylcholinesterase, and treatment was associated with improved learning and memory, higher brain superoxide dismutase levels, and better cortical and hippocampal histology.

A smaller set of publications addressed analytical and comparative aspects of empagliflozin use. One study developed and validated a second-derivative synchronous fluorescence method for simultaneous determination of empagliflozin and sitagliptin in tablets and plasma, reporting good sensitivity, linearity, accuracy, precision, and an eco-friendly profile. Overall, the recent literature portrays empagliflozin as a therapy with established cardiometabolic use, active comparative evaluation against dapagliflozin and DPP-4 inhibitors, and expanding experimental interest in renal, intestinal, myocardial, and neuroprotective mechanisms.

Key Publications

NEWJun Comparative effectiveness of dapagliflozin vs. empagliflozin on major adverse cardiovascular events in patients with heart failure with reduced ejection fraction: A real-world prospective cohort study. (British journal of clinical pharmacology, 2026, PMID 42357835): "Dapagliflozin and empagliflozin are sodium-glucose cotransporter-2 inhibitors (SGLT2i) with equivalent Class IA guideline recommendations in heart failure with reduced ejection fraction (HFrEF)."
NEWJun Head-to-head comparative effectiveness of empagliflozin versus dapagliflozin and DPP-4 inhibitors on clinical and metabolic outcomes: a nationwide propensity-matched study. (Scientific reports, 2026, PMID 42342812): "This retrospective study compared the clinical and metabolic effectiveness of empagliflozin (EMPA) versus dapagliflozin (DAPA) and dipeptidyl peptidase-4 inhibitors (DPP-4i) using real-world data from the Korean National Health Insurance Service (2013-2024)."
Jun Morin enhances the renoprotective effects of Empagliflozin in diabetic kidney disease via targeting ATF6-DAPK1 signaling. (Chinese journal of natural medicines, 2026, PMID 42215155): "This study examined the protective effects of Morin against hyperglycemia-induced renal tubular injury, alone or in combination with the SGLT2 inhibitor Empagliflozin, with emphasis on the ATF6-DAPK1 axis."
May Advanced glycation end-products exacerbate myocardial ischemia/reperfusion injury by promoting mitochondrial oxidative damage and PANoptosis in diabetes mellitus. (Redox biology, 2026, PMID 42176503): "Therapeutically, combination treatment with pyridoxamine (an AGEs inhibitor) and empagliflozin (an SGLT2 inhibitor) in diabetic mice potently suppressed AGEs accumulation, mitigated mitochondrial damage and PANoptosis, and significantly improved cardiac recovery post-MI/R."
May Eco-friendly second-derivative synchronous fluorescence method for the determination of empagliflozin and sitagliptin in tablets and plasma samples. (Scientific reports, 2026, PMID 42162103): "Empagliflozin and sitagliptin are commonly co-administered to manage type 2 diabetes mellitus due to their complementary mechanisms of action on renal glucose reabsorption and insulin secretion, respectively."
Jun Empagliflozin Restores the Colonic Mucous Barrier by an AMPK/SOX4-Dependent Pathway in Glycogen Storage Disease Type Ib. (FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026, PMID 42133539): "Although the SGLT2 inhibitor empagliflozin has demonstrated remarkable clinical efficacy, its direct effects on the intestinal epithelium remain poorly understood."
Jun Efficacy and safety of anagliptin added to metformin and empagliflozin 25 mg in patients with type 2 diabetes: a 24-week randomized, double-blind, placebo-controlled phase 3 trial with 28-week open-label extension. (Diabetes research and clinical practice, 2026, PMID 42036072): "This study evaluated the efficacy and safety of anagliptin added to metformin and empagliflozin in patients with type 2 diabetes (T2DM) inadequately controlled on dual therapy."
Jun Empagliflozin improves metabolism and prevents myocardial and coronary dysfunction in streptozotocin-diabetic and non-diabetic rats subjected to ischemia/reperfusion. (Basic research in cardiology, 2026, PMID 41995817): "The selective sodium-glucose cotransporter 2 inhibitor empagliflozin (EMPA) shows cardiovascular benefits in heart failure, type 2 diabetes and chronic kidney disease."
May Empagliflozin and dapagliflozin, sodium glucose cotransporter 2 inhibitors, may improve cognitive dysfunctions: in silico and in vivo findings. (Behavioural brain research, 2026, PMID 41819428): "In this context, the present study investigated the potential contributions of empagliflozin (EMPA) and dapagliflozin (DAPA) to cognitive function by evaluating their in silico interactions with targets associated with oxidative stress, inflammation, and neuroprotection, including SGLT1, SGLT2, acetylcholinesterase (AChE), superoxide dismutase (SOD), receptor for advance glycation end-products (RAGE), and interleukin (IL)-1β."